Projects per year
Search results
-
Active
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Webber, K. (Primary Chief Investigator (PCI))
23/12/24 → 22/12/29
Project: Research
-
A Randomized Phase 2 Study of Ocular Toxicity Evaluation and Mitigation During Treatment with Mirvetuximab Soravtansine in Patients with Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
21/10/24 → 20/10/29
Project: Research
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 Xport-EC-042 - A Phase 3, Randomized, placebo-controlled, double-blind, Multicenter trial of Selinexor in maintenance therapy after systemic therapy for patients with P53wild-type, advanced or recurrent endometrial carcinoma
Webber, K. (Primary Chief Investigator (PCI))
30/10/23 → 29/10/28
Project: Research
-
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting (KEYNOTE-C93/GOG-3064/ENGOT-en15)
Frentzas, S. (Primary Chief Investigator (PCI)) & Webber, K. (Primary Chief Investigator (PCI))
21/03/22 → 15/03/27
Project: Research
-
PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
27/01/22 → 26/01/27
Project: Research
-
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Webber, K. (Primary Chief Investigator (PCI))
25/11/20 → 24/11/25
Project: Research
-
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
Webber, K. (Primary Chief Investigator (PCI))
30/07/20 → 29/07/25
Project: Research